Jan Gerhartz

Congratulations to Jan Gerhartz for his first publication of a PhD in the Nowak Lab! Jan wrote a perspective article summarizing a new concept of bifunctional small molecules that can dimerize proteins and therefore generate a more potent and selective inhibitors. Small molecule inhibition relies on maintaining high occupancy of the protein target and are frequently limited for potency and selectivity. These types of inhibitors have been recently developed to target an E3 ubiquitin ligase KEAP1. KEAP1, controlled by the redox activity of the cell is known to degrade transcription factor Nrf2. Nrf2 is known for its importance in acute inflammatory conditions where activation has been shown to be protective against immunological challenge. Inhibitors of KEAP1 would result in upregulation of Nrf2 are therefore highly sought after. Jan puts a nice perspective on the novel idea of chemically linking two inhibitors together to form a single bifunctional molecule - strategy recently applied to KEAP1. These strategies could enable generation of molecules with improved selectivity and potency for many dimeric protein substrates.

You can read the full article here:
https://www.sciencedirect.com/science/article/abs/pii/S2451945624002150 


 

A new way to inhibit pyroptosis! Anja characterized by biochemical means six nanobodies that were raised against human Gasdermin D. All of them bind to the N-terminal domain of this membrane rupturing protein, but three specifically block the assembly of the membrane pore. She succeeded in crystallizing full length Gasdermin D together with two nanobodies and determined the structure at 1.9 Å resolution, providing first structural insights into the mode of action of nanobody-based Gasdermin D inhibition. Read the full story here.


We are very pleased to announce that Matthias has been awarded an ERC Advanced Grant for his proposal on the NLRP3 inflammasome. The EU will fund the work programme "Exploring inflammasome activation and targeted inhibition" (or "NalpACT" for short) for the next five years. Watch out, what comes out of this endeavour.


SR-4835, a small molecule inhibitor currently in phase I clinical trials, targets transcriptional kinases Cdk12 and Cdk13. Biochemical and structural analyses could highlight SR-4835’s selectivity towards Cdk12/Cdk13 over other CMGC kinase family members. We determined the crystal structure of the Cdk12/CycK heterodimer in complex with SR-4835 at 2.7Å resolution, revealing a unique hydrogen bond network mediated by the kinase hinge region. The structural insights provided offer a foundation for optimization and design of reversible Cdk12-specific inhibitors and could facilitate the basis for the development of novel cancer therapeutics. The full study from Max and coworkers is now published in The Journal of Biological Chemistry.


Inga and Matthias wrote a review article on the “Structural aspects of inflammasome-forming NOD-like receptors” for the book Fundamentals of Inflammasome Biology, edited by Pablo Pelegrín. In this review, they provide a state-of-the-art overview of the NLR family of proteins, from conserved sequence motifs to the quaternary assembly of the inflammasome; involving NLRP or NLRC sensory proteins, the adaptor ASC, and pro-caspases as downstream effectors. They discuss whether all NLRs function according to a similar mechanism and whether targeted inhibition appears feasible for the specific treatment of inflammatory diseases. Read this review here.